Clinical Research Directory
Browse clinical research sites, groups, and studies.
IV Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Heart Failure With Iron Deficiency
Sponsor: Hospital de Clinicas de Porto Alegre
Summary
Background. Treatment with intravenous iron has been shown to improve symptoms, functional capacity, and quality of life in patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency. However, the mechanisms underlying these beneficial effects remain unknown. SGLT2i seem to alter hematocrit and other hematological markers or iron content. This study aims to measure cardiac magnetic resonance changes in myocardial iron content and in left ventricular function after administration of intravenous iron with and without the concomitant use of SGLT2 inhibitor in patients with HFrEF and iron deficiency.
Official title: Effect of Combination of Intravenous Iron and SGLT2 Inhibitor on Ventricular Function and Myocardial Iron Content in Patients With Heart Failure and Iron Deficiency.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
99
Start Date
2024-05-24
Completion Date
2026-11-24
Last Updated
2024-06-03
Healthy Volunteers
No
Conditions
Interventions
Iron Carboxymaltose
Iron Carboxymaltose 500 mg. 2 vials administered IV.
Dapagliflozin 10mg Tab
Dapagliflozin 10mg Tab, PO, onde a day.
Placebo of Iron Carboxymaltose
Solution Sodium Chloride 0,9% 100 ml, IV, once.
Placebo of Dapagliflozin
Equal shape and appearance tab as the tab containing Dapagliflozin 10 mg
Locations (1)
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil